These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 26299425)

  • 1. Pharmacogenetics of Bisphosphonate-associated Osteonecrosis of the Jaw.
    Fung PL; Nicoletti P; Shen Y; Porter S; Fedele S
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):537-46. PubMed ID: 26299425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bisphosphonate and osteonecrosis of the jaw.].
    Taguchi A
    Clin Calcium; 2017; 27(2):225-231. PubMed ID: 28123124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics in medication-related osteonecrosis of the jaw: a systematic literature review.
    Bastida-Lertxundi N; Leizaola-Cardesa IO; Hernando-Vázquez J; Muguerza-Iraola R; Aguilar-Salvatierra A; Gómez-Moreno G; Crettaz JS
    Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10184-10194. PubMed ID: 31841171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiresorptive drug-related osteonecrosis of the jaw.
    Uyanne J; Calhoun CC; Le AD
    Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
    Dodson TB
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment.
    Otto S; Schreyer C; Hafner S; Mast G; Ehrenfeld M; Stürzenbaum S; Pautke C
    J Craniomaxillofac Surg; 2012 Jun; 40(4):303-9. PubMed ID: 21676622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw.
    Musolino C; Oteri G; Allegra A; Mania M; D'Ascola A; Avenoso A; Innao V; Allegra AG; Campo S
    Ann Hematol; 2018 Jul; 97(7):1259-1269. PubMed ID: 29546453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bisphosphonate-associated osteonecrosis of the jaws in lung cancer patients].
    Neves I; Morais A; Magalhães A
    Rev Port Pneumol; 2013; 19(5):228-32. PubMed ID: 23830508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database.
    de Boissieu P; Kanagaratnam L; Abou Taam M; Roux MP; Dramé M; Trenque T
    Pharmacoepidemiol Drug Saf; 2014 Sep; 23(9):989-92. PubMed ID: 24737486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.
    Khan AA; Sándor GK; Dore E; Morrison AD; Alsahli M; Amin F; Peters E; Hanley DA; Chaudry SR; Dempster DW; Glorieux FH; Neville AJ; Talwar RM; Clokie CM; Al Mardini M; Paul T; Khosla S; Josse RG; Sutherland S; Lam DK; Carmichael RP; Blanas N; Kendler D; Petak S; St-Marie LG; Brown J; Evans AW; Rios L; Compston JE;
    J Rheumatol; 2008 Jul; 35(7):1391-7. PubMed ID: 18528958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiology of Osteonecrosis of the Jaws.
    Aghaloo T; Hazboun R; Tetradis S
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):489-96. PubMed ID: 26412796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New approach to analyze genetic and clinical data in bisphosphonate-induced osteonecrosis of the jaw.
    Balla B; Vaszilko M; Kósa JP; Podani J; Takács I; Tóbiás B; Nagy Z; Lazáry A; Lakatos P
    Oral Dis; 2012 Sep; 18(6):580-5. PubMed ID: 22339777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Risk Factors for Bisphosphonate-Associated Atypical Femoral Fractures and Osteonecrosis of the Jaw in a Pharmacovigilance Database.
    Bejhed RS; Kharazmi M; Hallberg P
    Ann Pharmacother; 2016 Aug; 50(8):616-24. PubMed ID: 27179251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiresorptives and osteonecrosis of the jaw.
    Yamashita J; McCauley LK
    J Evid Based Dent Pract; 2012 Sep; 12(3 Suppl):233-47. PubMed ID: 23040351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate-associated osteonecrosis of the jaw: the rheumatologist's role.
    Capsoni F; Longhi M; Weinstein R
    Arthritis Res Ther; 2006; 8(5):219. PubMed ID: 17049069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study.
    Fung P; Bedogni G; Bedogni A; Petrie A; Porter S; Campisi G; Bagan J; Fusco V; Saia G; Acham S; Musto P; Petrucci MT; Diz P; Colella G; Mignogna MD; Pentenero M; Arduino P; Lodi G; Maiorana C; Manfredi M; Hallberg P; Wadelius M; Takaoka K; Leung YY; Bonacina R; Schiødt M; Lakatos P; Taylor T; De Riu G; Favini G; Rogers SN; Pirmohamed M; Nicoletti P; ; Fedele S
    Oral Dis; 2017 May; 23(4):477-483. PubMed ID: 28039941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventive Strategies for Patients at Risk of Medication-related Osteonecrosis of the Jaw.
    Goodday RH
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):527-36. PubMed ID: 26293331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic immunity shapes the oral microbiome and susceptibility to bisphosphonate-associated osteonecrosis of the jaw.
    Kalyan S; Wang J; Quabius ES; Huck J; Wiltfang J; Baines JF; Kabelitz D
    J Transl Med; 2015 Jul; 13():212. PubMed ID: 26141514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
    Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
    Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.